Zoetis
ZTS
79.11
-1.68
-2.08%
Zoetis
US · ZTS
#700 by market cap
Listed 1970
79.11
-1.68
-2.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:41
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 37 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 98.20% -0.50pp
- Institutions
- 1,783 -37
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund75.11%
Private Company7.44%
Public Company5.28%
Hedge Fund5.11%
Government Pension Fund2.27%
Sovereign Wealth Fund1.16%
Family Office/Trust0.54%
VC/PE Fund0.47%
Insurance Company0.40%
Other2.22%
Top holders as of 2026-06-30
BlackRock
9.54% · 39.43M sh
Vanguard Capital Management, LLC
6.87% · 28.39M sh
Vanguard Portfolio Management, LLC
5.77% · 23.86M sh
State Street Global Advisors
4.76% · 19.67M sh
State Farm Mutual Automobile Insurance Company
3.85% · 15.89M sh
Geode Capital Management, LLC
3.21% · 13.27M sh
Wellington Management Group
2.28% · 9.42M sh
UBS Asset Management
1.83% · 7.57M sh
Nordea Investment Management AB
1.60% · 6.59M sh
Deutsche Asset & Wealth Management
1.39% · 5.74M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 41 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Kristin Peck | Chief Executive Officer | 0.03% |
| Michael McCAllister | Independent Non-Executive Chairperson | 0.01% |
| Heidi Chen | Former Employee Advisor | 0.01% |
| Robert Scully | Former Independent Director | 0.01% |
| Louise Parent | Former Independent Director | 0.01% |
| Paul Bisaro | Independent Director | 0.01% |
| Wetteny Joseph | Special Advisor to the CEO | 0.01% |
| Frank D'Amelio | Independent Director | 0.01% |
| Gregory Norden | Independent Director | 0.00% |
| Roxanne Lagano | General Counsel | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-29 | Mark Stetter | Independent Director | Other Derivative Acquisition | +5 | -- |
| 2026-10-08 | Kristin Peck | Chief Executive Officer | Other Derivative Acquisition | +720 | -- |
| 2026-10-08 | Roxanne Lagano | General Counsel | Other Derivative Acquisition | +367 | -- |
| 2026-10-08 | Abhay Nayak | Executive VP & President of U.S. Commercial Operations | Other Derivative Acquisition | +321 | -- |
| 2026-10-08 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +367 | -- |
| 2026-10-08 | Jeannette Astorga | Executive VP of Corporate Affairs & Chief Sustainability Officer | Other Derivative Acquisition | +52 | -- |
| 2026-10-08 | Rimma Driscoll | EVP of Global Strategy, Portfolio Mkt, Busi. Dev Human Health and Platinum Per. | Other Derivative Acquisition | +277 | -- |
| 2026-10-08 | Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | Other Derivative Acquisition | +303 | -- |
| 2026-10-08 | Kevin Esch | Executive VP and President of Research & Development | Other Derivative Acquisition | +360 | -- |
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Sale | -274 | $69.83 |
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Retained | +525 | -- |
| 2026-09-16 | Mark Stetter | Independent Director | Other Derivative Acquisition | +342 | -- |
| 2026-08-30 | James Saccaro | Chief Financial Officer | Other Derivative Acquisition | +81,063 | -- |
| 2026-08-06 | Frank D'Amelio | Independent Director | Other Disposition | -6,650 | -- |
| 2026-07-09 | Wetteny Joseph | Special Advisor to the CEO | Other Derivative Acquisition | +363 | -- |
| 2026-07-09 | Kristin Peck | Chief Executive Officer | Other Derivative Acquisition | +616 | -- |
| 2026-07-09 | Roxanne Lagano | General Counsel | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Abhay Nayak | Executive VP & President of U.S. Commercial Operations | Other Derivative Acquisition | +214 | -- |
| 2026-07-09 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Jeannette Astorga | Executive VP of Corporate Affairs & Chief Sustainability Officer | Other Derivative Acquisition | +45 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:41:38 · For reference only, not investment advice and not tailored to your situation.
Zoetis discussion 0 comments